One Bridget Dintwe
One Dintwe currently holds the position of Research Officer in the Cape Town HIV Vaccine Trials Network (HVTN) Immunology Laboratory (CHIL) located in South Africa.
As a doctoral fellow at the South African TB Vaccine Initiative, at the University of Cape Town, One Dintwe carried out research to understand the role that memory T cells play in protecting against TB disease. She was involved in developing new tools to identify and perform an in-depth characterization of TB-specific memory T cells developed after vaccination with a novel TB vaccine, MVA85A, which went into a phase III efficacy trial. In 2015, she joined the HIV Vaccine Trials Network (HVTN) where she has been working on HIV clinical trial endpoints using the intracellular cytokine staining assay to determine which vaccines to take further in clinical trials. Her laboratory assesses cellular and innate immune responses to HIV and TB vaccines using technologies such as flow cytometry, multiplex protein detection, and next-generation sequencing. The lab standardized qualify, and validated assays conducted in a Good Clinical Laboratory Practice (GCLP)-compliant environment and assured assay concordance with the sister HVTN laboratory at the Fred Hutch in Seattle. One Dintwe experience focuses on measuring human immune responses to HIV and TB, primarily by flow cytometry, and application of systems biology approaches to understand disease pathogenesis and immune correlates of risk or protection, which can ultimately facilitate development and assessment of new vaccine.